Since its creation, the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC) has made a remarkable contribution to European and international cutting-edge research, as one of the largest RI for health research and in life sciences in Europe.… Read more 2023 marking its 10-year anniversary, BBMRI-ERIC is facing a unique moment to look into the long-term future and to develop its strategy for the next decade to ensure long-term sustainability. The EvolveBBMRI project aims to further develop BBMRI-ERIC for the benefit of its scientific communities and users, increase its capacity to serve EU policy priorities and further deepen its collaboration with industry. The project is structured in four thematic pillars: 1) Acceleration of datafication of biobanks and biomolecular resources to enable reproducible advanced medical research in support of EU health priorities ; 2) Teaming with industry towards greener biobanking; 3) Long-term sustainability measures for BBMRI addressing also RI landscape gaps; and 4) Strengthened approach for career paths, training and outreach activities to maximise impact. The project will ensure the implementation of specific results on 6 key target groups: a) Scientific community (Universities, Hospitals, Research Institutes); b) BBMRI-ERIC National Nodes, Biobanks in Europe and beyond; c) Industry and private foundations; d) Policy- and decision-makers at national and European levels; e) European and International networks and f) Donors, Patients and Citizens. EvolveBBMRI activities and outputs within its four Pillars will increase the long-term sustainability of BBMRI-ERIC and will thus contribute to a better structured and strengthened European research infrastructure landscape. Ultimately, the project will contribute to increase the scientific excellence to better tackle scientific and societal challenges and to expand and secure global competitiveness of the European Research Area

In line with the current guidelines for Safe and Sustainable by Design (SSbD) chemicals and materials, INTEGRANO proposes a general assessment approach based on quantitative evidence to be applied in practice for specific Nano Materials (NMs) design cases referred… Read more to inorganic, organic and carbon NMs. The development NMs dedicated novel impact categories (ICs) for nano-toxicity and eco-nanotoxicity assessment will enable the integrated application of standardised assessment methodologies. The following four NMs Life Cycle Stages (LCS) are addressed: synthesis, incorporation, use phase and end-of-life. The application of the stage-gate SSbD process through the LCS addresses performance in the five dimensions (5D s): Safety, Environmental, Economic, Social and Functional. Generation of dedicated response functions will allow associating Key Decision Factors (KDFs, such as: concentrations, processing parameters, etc.) to Key Performance Indicators (KPIs, such as: occupational safety, CO2 emissions, job creation potential, NM cost, antibacterial functionality, etc.). SSbD NMs solutions will be obtained by Multi Objective Optimisation Design (MOOD) dedicated algorithm. A dedicated digital Decision Support Toolbox (DST) will elaborate design case specific data and run MOOD algorithm to sort the set of multi-optimal SSbD options, which are simultaneously complying with all the targeted KPIs referred to the 5Ds. The digital supported decision process will help scientists, material engineers, Nano-Enabled Products (NEPs) designers, policymakers and decision-makers to takle the SSbD challenge, allowing for dramatic reduction of Research & Development (RTD) and approval leadtime as well as minimising costs and increasing the transparency of the data, by making the industrial uptake of nanotechnologies more sustainable and viable. INTEGRANO allows the integration with other existing SSbD frameworks by transposing results into other scoring metrics and enabling data exchange.

Which biomarker(s) are best suited to overcome current MRI interpretive issues and poor specificity in monitoring the effective response to therapy and the prediction of ARIA events? Irrespective of current legit debates on the clinical efficacy of amyloid-lowering therapeutics, several monoclonal antibodies… Read more (mAbs) are currently in clinical trials pipeline , including anti-TREM2 antagoist mAbs, or have entered accelerated FDA approval pathway. This means that 3 to 4 mAbs could potentially enter clinical practice in 2023. However, all of these high plaque-removing mAbs reported a common dose- and time-dependent incidence of ARIAs in up to 55% of the treated patients. In this framework, in order to minimize the risk of ARIAs, current trials limit enrollment to an extremely well-selected and radiographically monitored subpopulation of AD patients. Common criteria are the exclusion of patients with =5 cerebral microbleeds or cortical superficial siderosis at baseline and a control MRI before each biweekly/monthly infusion. This issue is challanging the generalizability of trials results, in particular concerning potential increased safety issues in real-word clinical settings. With 139 million of AD esteemed by 2050, and 60% of them living in low- and middle-income countries (2021 WHO report), longitudinal MRI monitoring plans for ARIA will hugely affect healthcare systems. This will potentially increase disparities, limiting accessibility to these therapeutics only to reach people and countries. In this framework, less costly and more accessible biomarkers will be of paramount importance for the future of AD immunotherapy. The UNIMIB-ARIA Toolkit Project aims at: 1) increase knowledge on the emerging evidence for neuroinflammation in the pathophysiology of ARIAs. 2) validate fluid-based biomarkers for improving diagnosis, prognosis, response to treatment, and prediction of ARIA-E recurrence compared to current state-of-the-art MRI images markers Thanks to the capillary activity and promotion we did in the last 10 years, including educational activities, at UNIMIB we are the National HUB for CAA and CAA-ri, receiving patients from almost all the main National centers (Spokes), the latter working as sub-spokes at regional and sub-regional level, in order to catch any patient also from very remote and rural areas. For these reasons, the National (Italy) biorepository should be considered an extremely excellent representation of the real-world clinical setting of the whole country. A gender-balanced Team (50% Female, 50% Male) of self-motivated and enthusiastic early career and young researcher composes the Teamwork. Addressing the aims of the UNIMIB-ARIA Project will be of paramount importance to increase generalizability and limit unnecessary restrictions to the future access of AD Therapeutics by the broaden community of AD and CAA patients, as well as to guide secondgeneration of more effective and safe therapeutics.

The BEFuture seeks to leverage talent, innovation and technology in support of the transformation of Europe’s MICE tourism sector into a regenerative, resilient and responsible industry. To this end, the project will work to engage the entire MICE ecosystem in the co-design… Read more of a new business model of events for Europe. Events that minimise their waste and carbon footprint, that are sustainable, inclusive and with positive and lasting impact. For that, it will set an open innovation space and network that generates ideas and exchanges knowledge for future industry growth. Using the Sustainable Development Goals framework, the project will identify best practices, and then develop talent, and build innovation capacity among SMEs and industry professionals, organising co-creation workshops and other innovation events that explore technologies, strategies, and trends, and bring together the people and professionals who will shape the future of the industry. Further, to bring forward this new generation of events, BEFuture will roll out an acceleration programme that will support at least 80 innovative projects from Belgium, France, Germany, Italy, Spain and the Netherlands, and a comprehensive communication and awareness-raising campaign, which will take advantage of major industry events such as the IBTM World, IMEX, and Mobile World Congress, amongst other. Overall, the project will contribute to strengthen the competitiveness of the European MICE tourism sector and turn Europe into a global benchmark of innovation, technology, and sustainability of the events’ industry. This enticing project is led by the Catalan Tourist Board, in coordination with Visit Flanders, BSOs such as Linkeus, VDVO and B.Link, and knowledge entities such as NHL Stenden – ETFI and University of Milano-Bicocca. Tipik will be the communication leader. BEFuture holds support from a wide network of ecosystem stakeholders, including Convention Bureaus, BSOs and international industry associations